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Epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), and ROS
proto-oncogene 1 (ROS1) are ‘must-test’ biomarkers in the molecular diagnostics of advan-
ced-stage lung cancer patients. Although single-gene assays are currently considered the
gold standard for these genes, next-generation sequencing (NGS) tests are being introduced
to clinical practices. We compared the results of current diagnostics and aimed to suggest
timely effective guidance for their clinical use.  
Materials and Methods
Patients with lung cancer who received both conventional single-gene assays and subse-
quent targeted NGS testing were enrolled, and the results of their tests were compared. 
Results
A total of 241 patients were enrolled, and the EGFR real-time polymerase chain reaction,
ALK fluorescence in situ hybridization (FISH), and ROS1 FISH assays exhibited 92.9%,
99.6%, and 99.5% concordance with the NGS tests, respectively. The discordant cases were
mostly false-negatives of the single-gene assays, probably due to technical limitation. Of
158 cases previously designated as wild-type, EGFR, ALK, and ROS1 alterations were iden-
tified in 10.1%, 1.9%, and 1.3%, respectively, and other targetable alterations were identified
in 36.1% of the cases. Of patients with additionally identified actionable alterations, 32.6%
(31/95) received matched therapy with a clinical benefit of 48.4% (15/31). 
Conclusion
Even though the conventional and NGS methods were concordant in the majority of cases,
NGS testing still revealed a considerable number of additional EGFR, ALK, and ROS1 alter-
ations, as well as other targetable alterations, in Korean advanced-stage lung cancer pati-
ents. Given the high frequency of EGFR and other targetable mutations identified in the
present study, NGS testing is highly recommended in the diagnosis of Korean lung cancer
patients.
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Introduction
The discovery of oncogenic alterations with sensitivity to
tyrosine kinase inhibitors (TKIs) has changed the therapeutic
landscape of lung cancer. In particular, epidermal growth
factor receptor (EGFR) mutations, anaplastic lymphoma 
kinase (ALK) rearrangements, and ROS proto-oncogene 1
(ROS1) rearrangements have been frequently used as thera-
peutic targets, and they are regarded as “must-test” biomark-
ers in the molecular diagnostics of advanced-stage lung
cancer patients [1]. Currently, single-gene assays, such as
real-time polymerase chain reaction (PCR), immunohisto-
chemistry (IHC), and fluorescence in situ hybridization (FISH)
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tests, are considered the gold standard for selecting eligible
patients for EGFR-, ALK-, and ROS1-specific TKI therapy
[1,2]. However, with the development of next-generation 
sequencing (NGS), other less common oncogenic alterations
with available therapies have been detected [3]. 
NGS is a high-throughput multiplex sequencing method
which is capable of identifying a variety of genetic alterations
simultaneously. In addition, targeted NGS carries out deep
sequencing of relevant targets and detects mutations with
low mutation levels with high sensitivity. Because of these
advantages, many studies have investigated the feasibility of
using NGS methods in clinical practice [4-6]. In Korea, as 
National Health Insurance reimbursement became available
in 2017, NGS testing has increasingly been used as a clinical
diagnostic method. However, high costs, specialized imple-
ments and bioinformatics, complex test processes, and rela-
tively long turnaround time hinder its implementation as a
standard method for detecting genetic alterations [1]. 
In this study, we aimed to compare the results of single-
gene assays and NGS testing for EGFR, ALK, and ROS1 and
assess the occurrence of false results associated with these
methods in the molecular diagnostics of lung cancer patients.
In addition, a comprehensive algorithm for selecting patients
for TKIs is proposed, which is not to leave appropriately
treatable patients behind. 
Materials and Methods
1. Patients
Lung cancer patients who received NGS testing at Yonsei
University Severance Hospital (Seoul, Korea) between July
2017 and March 2019 were enrolled. Clinical data, including
age, sex, and smoking history, were obtained from the pati-
ents’ medical records.
2. Single-gene EGFR assay
To detect EGFR mutations, peptide nucleic acid (PNA)-
mediated real-time PCR-based methods were performed
using the PNAClamp EGFR Mutation Detection Kit (Pana-
gene, Daejeon, Korea) or PANAMutyper EGFR Kit (Pana-
gene) according to manufacturer’s instructions. In PNA-
Clamp method, the efficiency and results of the test is deter-
mined by measuring threshold cycle (Ct) value. Ct value is a
PCR cycle number at which the fluorescent signal of the 
reaction crosses the threshold and it is inversely related to
the starting amount of target DNA. For data interpretation,
PNA clamped Ct value and non-PNA Ct value of patient
samples are measured. If non-PNA Ct value is between 22
and 30, the sample is regarded to have an appropriate qual-
ity. In addition, delta Ct (!Ct) values (!Ct1=standard Ct!
sample PNA Ct, !Ct2=sample PNA Ct!sample non-PNA Ct)
are calculated. !Ct1 < 0 indicates target mutation wild-type
of tested samples, while (1) !Ct1 " 2, or (2) 0 < !Ct1 < 2 and
!Ct2 # 3 is regarded presence of targeted mutation. The man-
ufacturer also described a possibility of suboptimal tests, if
!Ct1 is between 0 and 2 and non-PNA Ct value is between
24 and 30. In this case, the sample might have a low mutation
rate that re-test by using twice as high concentration of the
sample is recommended. 
3. Single-gene ALK and ROS1 assays
To identify ALK and ROS1 rearrangements, IHC was per-
formed using ALK (rabbit monoclonal, clone D5F3, Cell Sig-
naling Technology, Danvers, MA) and ROS1 (rabbit mono-
clonal, clone D4D6, Cell Signaling Technology) antibodies,
as previously described [7]. For IHC positive cases, FISH was
performed using a break-apart ALK or ROS1 probe (Vysis
LSI Dual Color, Break Apart Rearrangement Probe, Abbott
Molecular, Abbot Park, IL), and ALK or ROS1 rearrange-
ments were scored as positive when at least 15% of the tumor
cells exhibited split or isolated 3! signals.
4. NGS analysis
Targeted DNA and RNA sequencing were performed
using TruSight Tumor 170 (Illumina, San Diego, CA) or a
customized cancer panel (NgeneBio, Seoul, Korea). The
TruSight Tumor 170 panel was designed to detect 170 can-
cer-related genes, including 151 genes with potential single
nucleotide variants (SNVs) and indels, 59 genes with poten-
tial amplifications, and 55 genes with fusion and splice vari-
ants (S1 Table). The customized cancer panel was designed
to detect 46 cancer-related genes, including 46 genes with 
potential SNVs and indels, 20 genes with potential amplifi-
cation, and 17 genes with potential fusion variants (S2 Table).
Briefly, 40 ng of formalin-fixed paraffin-embedded (FFPE)
tissue-derived DNA and RNA were extracted using Qiagen
AllPrep DNA/RNA FFPE Kit (Qiagen, Hilden, Germany).
After hybridization capture-based target enrichment, paired-
end sequencing (2$150 bp) was performed using a NextSeq
sequencer (Illumina) according to the manufacturer’s instruc-
tions. Variants with a total depth of at least 100$ and variant
allele frequency of at least 3% was included for analysis.
Variant interpretation was based on recommendations from
the Association for Molecular Pathology, American Society
of Clinical Oncology, and College of American Pathologists
[8]. Actionable genetic alterations were stratified into one of
four levels based on OncoKB website (http://www.OncoKB.
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org). Tier 1 variant included level 1 and level 2 genetic alter-
ations that are Food and Drug Administration–approved
biomarkers and standard of care. Tier 2 variant included 
alterations with compelling clinical or preclinical evidence to
drug response.
5. Ethical statement
The present study was approved by the Institutional 
Review Board of Severance Hospital (No. 4-2019-0273), and
the requirement for written informed consent from the pati-




A total of 241 patients were enrolled in the present study
(Table 1). The patients included 110 men (45.6%) and 131
women (54.4%), and their age ranged from 28 to 85 years
(mean, 60.1 years). In addition, the population included 156
never smokers (64.7%), 64 former smokers (26.6%), and 21
current smokers (8.7%). The histological types consisted of
201 adenocarcinomas (83.4%), 11 non-small cell carcinomas-
not otherwise specified (4.6%), seven squamous cell carcino-
mas (2.9%), six invasive mucinous adenocarcinomas (2.5%),
six small cell carcinomas (2.5%), four sarcomatoid carcino-
mas (1.7%), three adenosquamous carcinomas (1.2%), and
three carcinoid tumors (1.2%). In NGS analysis, 205 cases
(85.1%) were tested with the TruSight Tumor 170 panel and
36 (14.9%) cases were tested with the customized cancer
panel. The NGS-tested specimens included 178 biopsies
(73.9%), 62 resections (25.7%), and one cytology (0.4%). The
average total read depth of the tests was approximately
1,000!.
All patients had previously received the PCR-based EGFR
and ALK IHC/FISH tests at the time of their initial diagnosis.
However, in one case, the ALK IHC and FISH tests had
failed, due to inadequate sample quality. In addition, 210 
patients (87.1%) had also received either the ROS1 IHC test,
ROS1 FISH test, or both. The remaining 31 patients (12.9%)
had initially been diagnosed at other hospitals and were sub-
ject to NGS testing at Severance Hospital without receiving
either the ROS1 IHC or ROS1 FISH analyses. All the NGS
tests were requested by corresponding oncologists with the
aim of identifying therapeutic targets or any alterations of
drug resistance in advanced-stage lung cancer patients. The
single-gene assays identified EGFR, ALK, and ROS1 alter-
ations in 66 (27.4%), five (2.1%), and 13 (5.4%) cases, respec-
tively, whereas NGS testing identified 82 (34.0%), eight
(3.3%), and 14 (5.8%) cases. The EGFR, ALK, and ROS1 alter-
ations were identified with mutual exclusivity.
2. Comparison of single-gene and NGS EGFR assays
Of the 241 cases screened for EGFR mutations, 224 cases
(92.9%) yielded concordant PCR and NGS results, whereas
17 (7.1%) yielded discordant results (Table 2). Of the 66 EGFR
PCR-positive cases, all cases returned positive NGS results,
however, one (1.5%) had discordant result. In the discordant
case, the PCR method had detected a deletion in exon 19
(E19del), whereas the NGS test had detected p.L747P in exon
19. Meanwhile, for the 175 PCR-confirmed wild-type cases,
159 (90.9%) yielded concordant PCR and NGS results. For
the 16 discordant cases (9.1%), NGS testing revealed new
EGFR mutations, including eight hotspot mutations and
eight rare mutations. 
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Table 1. Patient characteristics
SD, standard deviation; ADC, adenocarcinoma; SqCC,
squamous cell carcinoma; IMA, invasive mucinous ade-
nocarcinoma; NSCLC-NOS, non-small cell lung carcinoma
(not otherwise specified).
Characteristic No. (%) (n=241)





Never smoker 156 (64.7)
Former smoker 64 (26.6)







Adenosquamous carcinoma 3 (1.2)
Sarcomatoid carcinoma 4 (1.7)
IMA 6 (2.5)
NSCLC-NOS 11 (4.6)
Small cell carcinoma 6 (2.5)




Fluid cytology 1 (0.4)
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The eight EGFR hotspot mutations were the L858R muta-
tion (five cases), E19del (p.E746_A750del; two cases), and an
insertion in exon 20 (E20ins; p.H773delinsPNPY; one case)
which could be detected by PCR methods (Table 3). For five
cases, the PCR and NGS testing were performed on the same
samples, whereas for the other three cases, different samples
were used for PCR and NGS testing. Furthermore, Ct values
could be reviewed for four cases. Two cases yielded negative
!Ct1 values and non-PNA Ct values between 22 and 30,
which indicated as negative results with appropriate sample
quality. In the reports of other two cases, !Ct1 values bet-
ween 0 and 2, !Ct2 values ! 3, and their non-PNA Ct values
were between 24 and 30, which are interpreted as negative
results with low sample quality. 
The other eight PCR-negative NGS-positive cases harbored
EGFR mutations that were not targeted by the PCR method.
Of these, three cases were exon 18 indel or exon 19 deletion
and five cases were E20ins mutations. Four patients (50%)
were treated with EGFR TKI (Table 4). Patient A04 was
treated with gefitinib after identifying an EGFR mutation
(p.A750_I759>PL) and exhibited a partial response. How-
ever, treatment of other patients is ongoing that their thera-
peutic responses are unknown yet.
3. Comparison of single-gene and NGS ALK assays
A total of 238 cases (99.2%) yielded concordant ALK FISH
and NGS results, and two cases (0.8%) yielded discordant 
results (S3 Table). NGS testing confirmed that all the ALK
FISH-positive cases possessed ALK rearrangements. How-
ever, NGS testing also identified ALK rearrangements for
two of the 235 ALK FISH-negative cases. These two cases
were initially diagnosed at other hospitals, which had shown
positive ALK IHC results (+2/3), but negative ALK FISH 
results, with 8% and 9% of split signals, respectively. 
4. Comparison of single-gene and NGS ROS1 assays
A total of 209 cases (99.5%) yielded concordant ROS1 FISH
and NGS results, and only one case (0.5%) yielded discordant
results. For the discordant case, the ROS1 IHC test returned
diffuse moderate protein expression (+2/3), and the ROS1
FISH test returned 22% of split signals, whereas NGS identi-
fied non-functional (out-of-frame) RNR2 (chromosome 14)-
ROS1 (chromosome 6) fusion and newly identified the
deletion EGFR mutation in exon 18. The result of ROS1 real-
time PCR companion diagnostics was also negative.
5. Genetic alterations in previously documented wild-type
cases
Of the 158 cases denoted as wild-type on the basis of sin-
gle-gene assays, NGS testing identified 95 patients (60.1%)
who harbored actionable alterations. In addition to 16 EGFR
mutations (10.1%), the NGS testing revealed three ALK
fusions (1.9%), two ROS1 fusions (1.3%), five BRAF muta-
tions (3.2%), seven MET exon 14 skipping or amplification
(4.4%), nine RET fusions (5.7%), one NTRK2 fusion (0.6%)
and so on (Fig. 1). Of 95 patients with actionable alterations,
32.6% (31/95) received matched therapy and 48.4% (15/31)
Cancer Res Treat. 2020;52(2):543-551
Table 2.  Summary of single-gene assay and NGS results
NGS, next-generation sequencing; EGFR, epidermal growth factor receptor; PCR, polymerase chain reaction; ALK, anaplastic
lymphoma kinase; FISH, fluorescence in situ hybridization; ROS1, ROS proto-oncogene 1. a)One of the positive PCR results
was a false-positive because a base substitution was interpreted as a deletion mutation.
NGS positive NGS negative Total Concordance rate (%)
EGFR
PCR positive 66a) 0 66 92.9
PCR negative 16 159 175
Total 82 159 241
ALK
FISH positive 5 0 5 99.2
FISH negative 2 233 235
FISH failure 1 0 1
Total 8 233 241
ROS1
FISH positive 12 1 13 99.5
FISH negative 0 197 197
FISH not done 2 29 31
Total 14 227 241
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showed responses to therapy (S4 Table). The remaining pati-
ents were treated with palliative therapy due to poor general
condition, or received cancer immunotherapy, or expired.
Discussion
According to the NGS results of the present study, the
overall probabilities detecting of EGFR, ALK, and ROS1
alterations were 34.0%, 3.3%, and 5.8%, respectively. In our 
cohort, the NGS testing was primarily performed on clini-
cally selected patients who had EGFR/ALK-negative or ther-
apeutic non-responsive or resistant tumors. In contrast, ROS1
IHC/FISH tests were not performed during the initial diag-
nosis of patients that transferred from other hospitals, and a
considerable number of cases were subject to NGS test in our
institution without receiving either the ROS1 IHC or ROS1
FISH analyses. Therefore, the NGS-tested cohort was likely
enriched in EGFR/ALK-negative cases and could not reflect
the general characteristics of lung cancer patients. 
The aim of the present study was to compare the results of
single-gene assays and NGS testing and to assess the occur-
rence of false results associated with these methods in the
molecular diagnostics of lung cancer. The results presented
here indicate that false-negatives occasionally occur in sin-
gle-gene assays. Regarding NGS results as a final outcome,
EGFR PCR showed 80.3% of sensitivity and 99.4% of speci-
ficity, ALK FISH showed 71.4% of sensitivity and 100% of
specificity, and ROS1 FISH showed 100% of sensitivity and
99.5% of specificity. Positive predictive value of EGFR PCR
method, ALK FISH, and ROS1 FISH, was 98.9%, 100%, and
67.8%, respectively, and negative predictive value was 88.3%,
98.5%, and 100.0%, respectively (S5 Table). This finding sug-
gests the necessity of re-validating the results of the single-
gene assays, especially for negative EGFR assays.
One major reason that the EGFR PCR assay yielded false-
negatives is that the sensitivity of PCR is lower than that of
deep targeted NGS. In four cases with EGFR hotspot muta-
tions that were not detected by PCR, all Ct values indicated
negative results. However, in two cases of 0 < !Ct1 < 2, a
possibility of suboptimal tests was suggested. In these cases,
re-test by using twice as high concentration of the sample is
recommended. However, re-testing was difficult owing to
the small amount of remaining tissue after the pathological
and molecular examinations. 
It is also notable that a misleading positive result was 
obtained using the EGFR PCR method. In this case, the pos-
itive PCR result was based on the detection of E19del, whereas
the positive NGS result was based on the detection of E19
p.L747P. Because the EGFR PCR method used in this study
















































































































































































































































































































































































































































































































VOLUME 52 NUMBER 2 APRIL 2020  547
was designed to only detect deletion-type mutations in exon
19, the true alteration (i.e., base substitution) was misinter-
preted. This is concerning because the EGFR p.L747P muta-
tion had been rarely reported with relation to poor response
to gefitinib and erlotinib, in contrast to the favorable thera-
peutic response of E19del mutation [9-11]. Indeed, this spe-
cific case was resistant to gefitinib treatment, thereby con-
firming the conclusion that accurate mutation identification
can impact clinical management. 
Another inherent limitation of the PCR method is that only
targeted loci can be identified [12]. In this study, 3.3% of cases
with rare-type EGFR mutations were not detected using
PCR. Rare EGFRmutations had been reported to be observed
in male smokers with inferior EGFR TKI response [13,14].
However, recent studies have reported that rare EGFRmuta-
tions can be more effectively targetable with appropriate
TKIs [15]. Similarly, several recent studies have reported that
insertions in EGFR exon 20, which had been known to be 
resistant to first- or second-generation EGFR TKI treatments,
could be effectively targeted using new TKIs, such as pozio-
tinib [16-18]. Therefore, rare EGFRmutations could be equa-
lly important targets in the treatment of advanced-stage lung
cancer, and detailed information regarding EGFR mutation
type is needed to apply appropriate therapies. Based on our
Cancer Res Treat. 2020;52(2):543-551
Patient Sex Age Smoking EGFR VAF (%) PCR PCR-NGS
Specimen type  
ID (yr) (yr) status mutations method samples PCR NGS
A01 F 73 Never p.E709_T710delinsD 7.0 Clamp (O) Resampled Biopsy Biopsy
A04 F 44 Never p.A750_I759>PL 12.6 Clamp (O) Identical Biopsy Biopsy
A05 F 41 Never p.D770_N771insG 11.1 Clamp (O) Resampled Biopsy Biopsy
A06 M 61 Former p.D770_N771insGD 37.2 Clamp (I) Identical Biopsy Biopsy
A08 F 46 Never p.A767delinsASVD 4.2 Clamp (I) Identical Biopsy Biopsy
A09 M 64 Never p.A767_V769dup 25.0 Clamp (I) Identical Resection Resection
A10 F 62 Never p. D770_N771insGF 81.2 Clamp (O) Resampled Biopsy Biopsy
A16 F 67 Never p.E709_T710delinsD 75.0 Mutyper (I) Resampled Biopsy Resection
NGS, next-generation sequencing; EGFR, epidermal growth factor receptor; VAF, variant allele frequency; PCR, polymerase
chain reaction; O, outside hospital; I, in-house test.
Table 4. NGS-positive cases with discordant EGFR results with rare mutations











































Fig. 1. Next-generation sequencing (NGS)–detected alterations identified in 158 cases previously designated as wild-type.
(A) Distribution of potentially actionable genetic alterations. (B) Distribution of genetic alterations. Variant classification was
based on recommendations from the Association for Molecular Pathology, American Society of Clinical Oncology, and Col-
lege of American Pathologists [8]. EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; ROS1, ROS
proto-oncogene 1; IDH1, isocitrate dehydrogenase 1; FGFR1, fibroblast growth factor receptor 1; PIK3CA, phosphatidylinos-
itol-4, 5-bisphosphate 3-kinase catalytic subunit alpha; NF1, neurofibromin 1.
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finding, NGS testing could be used as a complementary
method to overcome the limitations of conventional PCR
methods. 
We also identified some limitations in the FISH assays,
with false-negative (n=2) and false-positive (n=1) results 
observed for the ALK FISH and ROS1 FISH assays, respec-
tively. For the two ALK FISH-negative cases, the FISH tests
had been performed at other hospitals. In both cases, the ALK
IHC results indicated moderate protein expression, whereas
the FISH results indicated low rates of split signals, which
implies that the false-negatives could have resulted from the
technical or interpretational aspects of FISH [19-21]. Notably,
both patients were eventually treated with crizotinib and
alectinib, respectively, and exhibited clinical responses.
Meanwhile, for the ROS1 FISH false-positive case, the fusion
identified by the FISH assay was determined to be a rare 
intronic fusion, which does not generate an active functional
protein change, and the error was further empowered by
non-specific positive ROS1 IHC results. 
Several other studies have also reported the possibility of
false results from FISH assays and have strongly suggested
that NGS be used to resolve IHC-FISH discordant cases
[20-24]. In addition, the re-validation of molecular testing
would be useful in the treatment of tumors that are unre-
sponsive to target agents. Currently, both ALK IHC and
ROS1 real-time PCR kits have been approved for use as com-
panion diagnostics in Korea and are expected to increase the
diagnostic yield of patients harboring gene fusions. How-
ever, when compared to NGS methods, these tests are lim-
ited in their ability to accurately identify fusion partners or
fusion variants that additional verification in clinical practice
may provide further insight.
In the present study, NGS testing identified EGFR/ALK/
ROS1 alterations in 13.3% of previously diagnosed as wild-
type cases using single-gene assay. These additional cases
were mostly females or never smokers, although males and
smokers were also included. In addition, other targetable 
alterations were identified in 36.1% of the “wild-type” cases.
These results might suggest the implementation of NGS as a
first-line test for molecular diagnostics of lung cancer. How-
ever, at the present time, it is still challenging to use NGS as





















Fig. 2. Proposed algorithm for the molecular diagnostics of advanced-stage lung cancer patients. In terms of turnaround
time and frequency of major genetic alterations, single-gene testing can be performed first. When results of single-gene assays
are negative or clinically indicated, next-generation sequencing (NGS) testing should be performed. The NGS testing can be
performed first, so this is also shown in this figure. EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma 
kinase; ROS1, ROS proto-oncogene 1; IHC, immunohistochemistry; FISH, fluorescence in situ hybridization.
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of specialized implements and bioinformatics of NGS. In 
addition, current resources for NGS analysis result in much
longer turnaround time compared to conventional tests. 
Regarding well-established single-gene assays in Korea and
high prevalence of EGFR mutations in Korean lung cancer
patients [25], single-gene tests are still indispensable. Thus,
we recommend maintaining single-gene tests as first-line
tests and actively use NGS for re-validation of the negative
results. Oncologists and pathologists should consider the
limitations of conventional methods and re-validate the 
results of these methods, especially when targetable alter-
ations are not detected in females or never smokers, targets
are detected but no therapeutic response is observed, or neg-
ative results could be the product of insufficient sample
quantity (Fig. 2). Notably, in our cohort, of patients with 
additionally identified actionable alterations, 32.6% received
matched therapy with a clinical benefit of 48.4%. These 
results are similar to those described in the report by Jordan
et al. [3].
There are some limitations to our study. First, this study
was limited by its retrospective design. Second, as previously
mentioned, our cohort does not reflect the general character-
istics of advanced-stage lung cancer patients, since the NGS-
tested cohort was likely enriched in EGFR/ALK-negative
cases and since a high proportion of the patients were female
or never smokers.
In conclusion, even though the conventional and NGS
methods were concordant in the majority of cases, NGS test-
ing still revealed a considerable number of additional EGFR,
ALK, and ROS1 alterations, as well as other targetable alter-
ations, in Korean advanced-stage lung cancer patients. Given
the high frequency of EGFR and other targetable mutations
identified in the present study, NGS testing is highly recom-
mended in the diagnosis of Korean lung cancer patients.
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